Autonomix receives Canadian patent for nerve therapy technology
Autonomix Medical Inc., a medical device company, has secured a Canadian patent for its innovative nerve therapy technology. The patent, number 3,183,802, was issued by the Canadian Intellectual Property Office and covers catheter-based transvascular intervention techniques. Autonomix's systems, methods, and devices are designed to monitor and treat tissues within or through a lumen wall, allowing deployable probes to access tissue and nerves outside the vessel.
The patent protects multi-site electrophysiological sensing capabilities and methods for assessing procedural completion based on real-time feedback, enabling systems to adjust stimulation or therapeutic energy delivery accordingly. With 112 issued or pending patent applications worldwide, the company's intellectual property portfolio extends into the late 2030s.
Autonomix Medical's technology, currently investigational and unapproved for marketing in the United States, has the potential to impact multiple nerve-targeted indications, with claims covering various electrophysiological signal types and therapeutic modalities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.